Biological Sciences Division
Published October 28, 2024 | Version v1
Journal article Open

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011

Creators

  • 1. University of Chicago
  • 2. Université Paris-Saclay
  • 3. Jász-Nagykun-Szolnok County Hospital
  • 4. National Cancer Center Hospital East
  • 5. Yonsei University
  • 6. Sungkyunkwan University
  • 7. Federal Medical-Biological Agency
  • 8. Istanbul Medeniyet University
  • 9. Tülay Aktas Oncology Hospital
  • 10. University of Washington
  • 11. Erasmus MC Cancer Institute
  • 12. GUARD Consortium
  • 13. Queen Mary University of London
  • 14. Oregon Health & Science University
  • 15. Merck & Co.
  • 16. Eisai, Ltd.
  • 17. LUXMED Oncology
  • 18. University of Texas

Description

Background: First-line pembrolizumab monotherapy is a standard of care for platinum-ineligible patients with advanced urothelial carcinoma (UC). No global standardized definition of platinum ineligibility exists. This study aimed to evaluate the efficacy and safety of pembrolizumab monotherapy in patients with UC who met various criteria for platinum ineligibility.

Methods: Patients from KEYNOTE-052 and LEAP-011 deemed potentially platinum ineligible were pooled for this post hoc exploratory analysis as follows: group 1: Eastern Cooperative Oncology Group performance status (ECOG PS) 2; group 2: ECOG PS 2 and age ≥80 years, renal dysfunction, or visceral disease; and group 3: any two other factors regardless of ECOG PS. Patients received pembrolizumab 200 mg intravenously every 3 weeks. End points included objective response rate (ORR), progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1, by blinded independent central review, overall survival (OS), and safety.

Results: A total of 612 patients treated with pembrolizumab from KEYNOTE-052 (n = 370) and LEAP-011 (n = 242) were included; the median (range) follow-up was 56.3 months (51.2-65.3 months) and 12.8 months (0.2-25.1 months), respectively. For group 1, ORR was 26.2%, median PFS was 2.7 months, and median OS was 10.1 months. For group 2, ORR ranged from 23.5% to 33.3%, median PFS ranged from 2.1 to 4.4 months, and median OS ranged from 9.1 to 10.1 months. For group 3, ORR ranged from 25.7% to 27.9%, median PFS ranged from 2.1 to 2.8 months, and median OS ranged from 9.0 to 10.6 months. Treatment-related adverse event rates were consistent across groups.

Conclusions: Frontline pembrolizumab has consistent antitumor activity and safety in patients with advanced UC categorized as potentially ineligible for platinum-based chemotherapy, regardless of the variable definitions of platinum ineligibility used.

Data availability

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc (Rahway, New Jersey, USA) (MSD), is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company's clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data-sharing website (http://engagezone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the United States and European Union or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country- or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.

Files

Efficacy-and-safety-of-pembrolizumab-in-patients.pdf

Files (805.8 kB)

Name Size Download all
md5:0c23c1ecdc91345c5628908f36fc8e81
19.9 kB Download
Article
md5:aed8db21e4ac7847531386b2a55cbc48
785.9 kB Preview Download

Additional details

Identifiers

DOI
10.1002/cncr.35601
Other
oai:uchicago.tind.io:13950

Funding

Merck Sharp & Dohme LLC

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Medicine